Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Co.'s primary product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells in development for the treatment of Duchenne muscular dystrophy. Co. has also developed CAT-5571 as a potential treatment for cystic fibrosis (CF). CAT-5571 is an oral small molecule that is designed to activate autophagy, a mechanism for recycling cellular components and digesting pathogens, which is important for host defenses and is depressed in CF.

CATB — News

CATB — Price Chart